Twist Bioscience Corp
TWST35.320USD
+0.580+1.67%
Cierre 01/09, 16:00（ET）Cotizaciones retrasadas 15 min
2.14BCap. mercado
PérdidaP/E TTM
Más Datos de Twist Bioscience Corp Compañía
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Información de Twist Bioscience Corp
Símbolo de cotizaciónTWST
Nombre de la empresaTwist Bioscience Corp
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoLeproust (Emily M)
Número de empleados979
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección681 Gateway Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono18007190671
Sitio Webhttps://www.twistbioscience.com/
Símbolo de cotizaciónTWST
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoLeproust (Emily M)
Ejecutivos de Twist Bioscience Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
123.75K
-85020.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
37.56K
-9632.00%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
23.68K
+1436.00%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
17.16K
+1344.00%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
10.39K
+4834.00%
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
123.75K
-85020.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
37.56K
-9632.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
225.58M
59.90%
EMEA
124.24M
32.99%
APAC
26.75M
7.10%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
10.98%
Artisan Partners Limited Partnership
10.46%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
Otro
54.55%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
10.98%
Artisan Partners Limited Partnership
10.46%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
Otro
54.55%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
66.13%
Investment Advisor/Hedge Fund
36.09%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.69%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
570
73.25M
119.55%
-1.03M
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
6.73M
10.98%
+326.37K
+5.10%
Sep 30, 2025
Artisan Partners Limited Partnership
6.41M
10.46%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.76M
9.39%
-63.16K
-1.09%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.81M
7.85%
-46.27K
-0.95%
Sep 30, 2025
William Blair Investment Management, LLC
4.14M
6.76%
+235.68K
+6.03%
Sep 30, 2025
EdgePoint Investment Group Inc.
4.08M
6.66%
+1.70M
+71.10%
Sep 30, 2025
State Street Investment Management (US)
3.09M
5.04%
+588.07K
+23.51%
Sep 30, 2025
Amova Asset Management Co., Ltd.
2.12M
3.46%
-179.23K
-7.79%
Sep 30, 2025
Soleus Capital Management, L.P.
1.87M
3.05%
+1.51M
+426.59%
Sep 30, 2025
Millennium Management LLC
1.79M
2.93%
+1.08M
+151.55%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
Ver más
ARK Genomic Revolution ETF
Proporción6.24%
iShares Genomics Immunology and Healthcare ETF
Proporción3.92%
Global X Genomics & Biotechnology ETF
Proporción2.09%
ROBO Global Healthcare Technology & Innovation ETF
Proporción2%
WisdomTree BioRevolution Fund
Proporción1.79%
ARK Innovation ETF
Proporción1.47%
Franklin Genomic Advancements ETF
Proporción1.17%
State Street SPDR S&P Biotech ETF
Proporción0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.66%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.56%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Twist Bioscience Corp?
Los cinco principales accionistas de Twist Bioscience Corp son:
ARK Investment Management LLC posee 6.73M acciones, lo que representa el 10.98% del total de acciones.
Artisan Partners Limited Partnership posee 6.41M acciones, lo que representa el 10.46% del total de acciones.
The Vanguard Group, Inc. posee 5.76M acciones, lo que representa el 9.39% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.81M acciones, lo que representa el 7.85% del total de acciones.
William Blair Investment Management, LLC posee 4.14M acciones, lo que representa el 6.76% del total de acciones.
ARK Investment Management LLC posee 6.73M acciones, lo que representa el 10.98% del total de acciones.
Artisan Partners Limited Partnership posee 6.41M acciones, lo que representa el 10.46% del total de acciones.
The Vanguard Group, Inc. posee 5.76M acciones, lo que representa el 9.39% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.81M acciones, lo que representa el 7.85% del total de acciones.
William Blair Investment Management, LLC posee 4.14M acciones, lo que representa el 6.76% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Twist Bioscience Corp?
Los tres principales tipos de accionista de Twist Bioscience Corp son:
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
¿Cuántas instituciones poseen acciones de Twist Bioscience Corp (TWST)?
A fecha de 2025Q4, 570 instituciones poseen acciones de Twist Bioscience Corp, con un valor de mercado combinado de aproximadamente 73.25M, lo que representa el 119.55% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 0.46%.
¿Cuál es la mayor fuente de ganancias de Twist Bioscience Corp?
El FY2025, el segmento empresarial NGS tools generó la ganancia más alta para Twist Bioscience Corp, ascendiendo a 208.10M y representando el 55.26% de la ganancia total.
